Physician profile
Nigel M Azer
NPI 1255336178
$412.03
in general payments reported to CMS, 2019-2025
12 companies · $61.84 in 2025
The $61.84 reported for 2025 was less than what a typical Adult Reconstructive Orthopaedic Surgery provider received nationally (typical 2025 total: $1,425).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98.18 · 2020: $40.04 · 2021: $70.89 · 2022: $105 · 2023: $36.47 · 2025: $61.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $98.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $98.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $76.92 | 2019-2021 | |
| Bioventus LLC | $58.55 | 2019-2021 | |
| Stryker Corporation | $56.99 | 2019-2020 | |
| Carbofix Orthopedics INC | $38.56 | 2022 | |
| Depuy Synthes Sales INC. | $37.83 | 2022 | |
| Davol INC. | $29.28 | 2025 | Arista |
| Smith+Nephew, INC. | $28.22 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $22.90 | 2023 | Zilretta, Iovera |
| Orthofix Medical, INC. | $18.94 | 2025 | Physio-Stim |
| Ermi LLC | $16.65 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $13.62 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $13.57 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nigel Azer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.